05-1047
Anti-EGFR (cytoplasmic domain) Antibody, clone 8G6.2
clone 8G6.2, from mouse
Sinónimos:
Receptor tyrosine-protein kinase ErbB-1, avian erythroblastic leukemia viral (v-erb-b) oncogene
homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor, epidermal growth factor recepto
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
origen biológico
mouse
Nivel de calidad
forma del anticuerpo
purified antibody
tipo de anticuerpo
primary antibodies
clon
8G6.2, monoclonal
reactividad de especies
rat, mouse, human
técnicas
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: 1:2,000 using A431 cell lysate (used to detect EGFR)
western blot: suitable
isotipo
IgG1κ
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
wet ice
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... EGFR(1956)
mouse ... Egfr(13649)
rat ... Egfr(24329)
Descripción general
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor alpha (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of five tyrosine (Y) residues in the C-terminal domain of EGFR occurs. These are Y992, Y1045, Y1068, Y1148 and Y1173. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
Especificidad
This antibody detects the cytoplasmic domain of EGFR.
Inmunógeno
Recombinant protein encoding the cytoplasmic domain (C-terminal) of human EGF Receptor.
Aplicación
Detect EGFR (cytoplasmic domain) using this Anti-EGFR (cytoplasmic domain) Antibody, clone 8G6.2 validated for use in IC, IH, IP & WB.
Immunocytochemistry Analysis:
A431 cells were grown, fixed, permeablized, and stained with anti-EGFR, clone 8G6.2
Confocal Immunocytochemistry Analysis:
A431 cells were grown, fixed, permeablized, and stained with anti-EGFR, clone 8G6.2
Immunoprecipitation:
100 μg of A431 whole cell lysate was lysed in RIPA buffer and immunoprecipitated (IP) with 5 μg of Anti-EGFR, cytoplasmic domain, clone 8G6.2
Immunohistochemistry Analysis:
Tissue was stained with anti-EGFR, cytoplasmic domain, clone 8G6.2 at a 1:100 dilution and IHC-Select Detection with HRP-DAB reagents.
A431 cells were grown, fixed, permeablized, and stained with anti-EGFR, clone 8G6.2
Confocal Immunocytochemistry Analysis:
A431 cells were grown, fixed, permeablized, and stained with anti-EGFR, clone 8G6.2
Immunoprecipitation:
100 μg of A431 whole cell lysate was lysed in RIPA buffer and immunoprecipitated (IP) with 5 μg of Anti-EGFR, cytoplasmic domain, clone 8G6.2
Immunohistochemistry Analysis:
Tissue was stained with anti-EGFR, cytoplasmic domain, clone 8G6.2 at a 1:100 dilution and IHC-Select Detection with HRP-DAB reagents.
Calidad
Evaluated by western blot on A431 cell lysate
Western Blot Analysis:
1:2,000 dilution of this antibody was used to detect EGFR in A431 cell lysate.
Western Blot Analysis:
1:2,000 dilution of this antibody was used to detect EGFR in A431 cell lysate.
Descripción de destino
180 kDa
Ligadura / enlace
Replaces: 04-338
Forma física
Format: Purified
Otras notas
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Opcional
Referencia del producto
Descripción
Precios
Código de clase de almacenamiento
12 - Non Combustible Liquids
Clase de riesgo para el agua (WGK)
WGK 1
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Rajalakshmi Ramamoorthy et al.
Biology, 12(8) (2023-08-26)
Signs and symptoms involving multiple organ systems which persist for weeks or months to years after the initial SARS-CoV-2 infection (also known as PASC or long COVID) are common complications of individuals with COVID-19. We recently reported pathophysiological changes in
Akiyoshi Komuro et al.
International journal of cancer, 142(8), 1627-1639 (2017-12-02)
Glioblastoma is one of the most malignant forms of cancer, for which no effective targeted therapy has been found. Although The Cancer Genome Atlas has provided a list of fusion genes in glioblastoma, their role in progression of glioblastoma remains
Rory Mitchell et al.
Neurobiology of disease, 142, 104961-104961 (2020-06-13)
Effective analgesic treatment for neuropathic pain remains an unmet need, so previous evidence that epidermal growth factor receptor inhibitors (EGFRIs) provide unexpected rapid pain relief in a clinical setting points to a novel therapeutic opportunity. The present study utilises rodent
Laura A Laviolette et al.
Nature communications, 8, 15866-15866 (2017-06-29)
Germline mutations in the Folliculin (FLCN) tumour suppressor gene result in fibrofolliculomas, lung cysts and renal cancers, but the precise mechanisms of tumour suppression by FLCN remain elusive. Here we identify Rab7A, a small GTPase important for endocytic trafficking, as
Przemyslaw Solek et al.
Toxicological research, 38(2), 175-186 (2022-04-14)
The increasing number of depression cases leads to a greater need for new antidepressant treatment development. It is postulated that antidepressants may harm male fertility, but the cellular mechanism is still poorly understood. The role of growth factors and klotho
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico